![Clinical medicine / Medicine / Breakthrough therapy / Cancer / B-cell chronic lymphocytic leukemia / Obinutuzumab / Ofatumumab / Ibrutinib / Rituximab / Leukemia / Idelalisib / Phosphoinositide 3-kinase inhibitor Clinical medicine / Medicine / Breakthrough therapy / Cancer / B-cell chronic lymphocytic leukemia / Obinutuzumab / Ofatumumab / Ibrutinib / Rituximab / Leukemia / Idelalisib / Phosphoinositide 3-kinase inhibitor](https://www.pdfsearch.io/img/4bf63a8d0d6479c1f00a8b39cf015f4e.jpg) Date: 2015-07-22 04:38:28Clinical medicine Medicine Breakthrough therapy Cancer B-cell chronic lymphocytic leukemia Obinutuzumab Ofatumumab Ibrutinib Rituximab Leukemia Idelalisib Phosphoinositide 3-kinase inhibitor | | Interim statement from the BCSH CLL Guidelines Panel George A Follows1, Adrian Bloor2, Claire Dearden3, Steve Devereux4, Christopher P Fox5, Peter Hillmen6, Ben Kennedy7, Helen McCarthy8, Nilima Parry-Jones9, Piers EM PaAdd to Reading ListSource URL: www.bcshguidelines.comDownload Document from Source Website File Size: 553,43 KBShare Document on Facebook
|